» Articles » PMID: 15100299

Induction in Humans of CD8+ and CD4+ T Cell and Antibody Responses by Sequential Immunization with Malaria DNA and Recombinant Protein

Abstract

Vaccine-induced protection against diseases like malaria, AIDS, and cancer may require induction of Ag-specific CD8(+) and CD4(+) T cell and Ab responses in the same individual. In humans, a recombinant Plasmodium falciparum circumsporozoite protein (PfCSP) candidate vaccine, RTS,S/adjuvant system number 2A (AS02A), induces T cells and Abs, but no measurable CD8(+) T cells by CTL or short-term (ex vivo) IFN-gamma ELISPOT assays, and partial short-term protection. P. falciparum DNA vaccines elicit CD8(+) T cells by these assays, but no protection. We report that sequential immunization with a PfCSP DNA vaccine and RTS,S/AS02A induced PfCSP-specific Abs and Th1 CD4(+) T cells, and CD8(+) cytotoxic and Tc1 T cells. Depending upon the immunization regime, CD4(+) T cells were involved in both the induction and production phases of PfCSP-specific IFN-gamma responses, whereas, CD8(+) T cells were involved only in the production phase. IFN-gamma mRNA up-regulation was detected in both CD45RA(-) (CD45RO(+)) and CD45RA(+)CD4(+) and CD8(+) T cell populations after stimulation with PfCSP peptides. This finding suggests CD45RA(+) cells function as effector T cells. The induction in humans of the three primary Ag-specific adaptive immune responses establishes a strategy for developing immunization regimens against diseases in desperate need of vaccines.

Citing Articles

Malaria Vaccines: From the Past towards the mRNA Vaccine Era.

Tsoumani M, Voyiatzaki C, Efstathiou A Vaccines (Basel). 2023; 11(9).

PMID: 37766129 PMC: 10536368. DOI: 10.3390/vaccines11091452.


Malaria Vaccines: Progress to Date.

Stanisic D, Good M BioDrugs. 2023; 37(6):737-756.

PMID: 37728713 PMC: 10581939. DOI: 10.1007/s40259-023-00623-4.


mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum.

Hayashi C, Cao Y, Clark L, Tripathi A, Zavala F, Dwivedi G NPJ Vaccines. 2022; 7(1):155.

PMID: 36456563 PMC: 9715627. DOI: 10.1038/s41541-022-00577-8.


SILVI, an open-source pipeline for T-cell epitope selection.

Pissarra J, Dorkeld F, Loire E, Bonhomme V, Sereno D, Lemesre J PLoS One. 2022; 17(9):e0273494.

PMID: 36070252 PMC: 9451077. DOI: 10.1371/journal.pone.0273494.


Computational design of a broad-spectrum multi-epitope vaccine candidate against seven strains of human coronaviruses.

Kumar A, Rathi E, Kini S 3 Biotech. 2022; 12(9):240.

PMID: 36003896 PMC: 9395775. DOI: 10.1007/s13205-022-03286-0.